retatrutide triple agonist clinical trial Reta data & dosing β a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health β targeting GLP-1, GIP π¨ Today, retatrutide, the GIP/GLP-1/glucagon
Pay in 4 interest-free payments of $6.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Jul 31 - Aug 5





























